Haystack Oncology has developed a highly sensitive minimal-residual disease (MRD) testing technology, based on circulating tumor DNA (ctDNA), to aid in the early detection of residual or recurring cancer and better inform therapy decisions.
Acquired back in April, the acquisition will leverage Quest’s expertise and scale in oncology, genomics and pathology. Quest expects to incorporate this MRD technology into the development of new blood-based clinical lab services for solid tumor cancers available beginning in 2024.
Two of the biggest challenges facing healthcare R&D are the sheer volume of data and the unique characteristics of every person’s health. Artificial intelligence (AI)
Recently, the fervor over artificial intelligence has given way to expressions of fears of the unknown. The excitement of the democratization of technology has also
Welcome to Culture Clinic, MedPage Today‘s collaboration with Northwell Health to offer a healthcare professional’s take on the latest viral medical topics. Until this past
Quest Diagnostics Completes Acquisition of Haystack Oncology
by Healthcare M&A Leave a Comment
What You Should Know:
Streamlining healthcare with AI for drug development – Pharmaceutical Technology
Two of the biggest challenges facing healthcare R&D are the sheer volume of data and the unique characteristics of every person’s health. Artificial intelligence (AI)
Policymakers who want to regulate AI need to start talking to health care industry representatives
Recently, the fervor over artificial intelligence has given way to expressions of fears of the unknown. The excitement of the democratization of technology has also
Treating a Double Trouble Shark Attack
Welcome to Culture Clinic, MedPage Today‘s collaboration with Northwell Health to offer a healthcare professional’s take on the latest viral medical topics. Until this past